Synribo and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Synribo (omacetaxine mepesuccinate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Invokamet, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Nosebleed when taking Synribo. It is created by eHealthMe based on reports of 799 people who have side effects when taking Synribo from the FDA, and is updated regularly.

What is Synribo?

Synribo has active ingredients of omacetaxine mepesuccinate. eHealthMe is studying from 799 Synribo users. Check the latest studies of Synribo.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,091 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 12, 2026

799 people reported to have side effects when taking Synribo.
Among them, 13 people (1.63%) have Nosebleed.

Among these 13 people:

How long have people been on Synribo when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Synribo? *

female: 0.0 %
male: 100 %

What is the age of people who have Nosebleed when taking Synribo? *

What are other drugs people take besides Synribo? *

What are other side effects people have besides Nosebleed? *

Nausea (feeling of having an urge to vomit): 9 people, 69.23%
Thrombocytopenia (decrease of platelets in blood): 4 people, 30.77%
Dyspnea (difficult or laboured breathing): 4 people, 30.77%
Muscle Aches (muscle pain): 4 people, 30.77%
Fatigue (feeling of tiredness): 3 people, 23.08%
Fever: 2 people, 15.38%
Nausea And Vomiting: 2 people, 15.38%
Weakness: 2 people, 15.38%
Renal Disorder (kidney disease): 2 people, 15.38%
Feeling Hot: 1 person, 7.69%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 11 people, 84.62%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 7.69%
Nausea (feeling of having an urge to vomit): 1 person, 7.69%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 7.69%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 7.69%
Infection: 1 person, 7.69%
High Blood Cholesterol: 1 person, 7.69%
Faeces Hard: 1 person, 7.69%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 1 person, 7.69%
Diabetes: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Synribo and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Synribo:

Synribo (799 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Synribo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,091 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on omacetaxine mepesuccinate (the active ingredients of Synribo) and Synribo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.